1[1]Chapuy MC,Arlot ME,Duboeuf F,et al.Vitamin D3 and calcium to prevent hip fractures in the elderly women[J].N Engl J Med,1992,327 (23):1637-1642.
2[2]Reid IR,Ames RW,Evans MC,et al.Long-tem effects of calcium supplementation on bone loss and fractures in postmenopausal women a randomized controlled trial[J].Am J Med,1995,98(4):331-335.
3[3]Porthouse J,Cockayne S,King C,et al.Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care[J].BMJ,2005,330(7498):1003-1006.
4[4]Jackson RD,LaCroix A Z,Gass M,et al.Calcium plus Vitamin D supplementation and the risk of fractures[J].N Engl J Med,2006,354(7):669-683.
5[5]Effects of hormone therapy on bone mineral density:results from the postmenopausal estrogen/progestin interventions (PEPI) trial,the writing group for the PEPI[J].JAMA,1996,276(17):1389-1396.
6[6]Writing group for the women's health initiative investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the women's health initiative randomized controlled trial[J].JAMA,2002,288 (3):321-333.
7[7]Stefanick ML,Anderson GL,Margolis KL,et al.Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy[J].JAMA,2006,295 (14):1647-1657.
9[9]Ettinger B,Black DM,Mitlak BH,et al.Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene.Results from a 3-year randomized clinical trial[J].JAMA,1999,282 (7):637-645.
10[10]Delmas PD,Ensrud KE,Adachi JD,et al.Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis:four-year results from a randomized clinical trial[J].J Clin Endocrinol Metab,2002,87 (8):3609-3617.
二级参考文献2
1HulleyS ,,GradyD,BushT ,etal.Randomizedtrialofestrogenplusprogestinforsecondarypreventionofcoronaryheartdiseaseinpostmenopausalwomen[].The Journal of The American Medical Association.1998
2Writing Group for the Women′s Health Initiative Investigators.Risk and benefits of estrogen plus progestin in healthy postmenopausal women:principal results form the Women′s Health Initiative randomized controlled trial[].The Journal of The American Medical Association.2002
9Lee S,im JM,Chung CS,et al.Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in orean patients[J].Arch Pharm Res,2003,26(11):967-72.
10Carey AH,Waterworth D,Patel,et al.Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17[J].Hum Mol Genet,1994,3(10):1873-6.
